


Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof



wherein

L_1 is -O-;

L_2 is -CH₂-;

R_1 is selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, wherein the above C₁₋₁₀ alkyl is optionally substituted by one or more R_4 ;

R_2 is selected from the group consisting of hydrogen, cyano, COOH and -CONH₂;

B is selected from the group consisting of aryl and heteroaryl;

L_3 is selected from the group consisting of C₀₋₆ alkylene and imino, wherein the above C₀₋₆ alkylene and imino are optionally substituted by one or more R_4 ;

R_3 is selected from the group consisting of hydrogen, amino, C₁₋₁₀ alkyl, C₃₋₁₀ cyclohydrocarbyl and 3-10 membered heterocyclohydrocarbyl, wherein the above amino, C₁₋₁₀ alkyl, C₃₋₁₀ cyclohydrocarbyl and 3-10 membered heterocyclohydrocarbyl are optionally substituted by one or more R_4 ; or

R_3 and L_3 together with the adjacent atom at the ring B form a saturated or unsaturated 5-8 membered ring, the 5-8 membered ring is optionally substituted by one or more R_4 ;

n is 0, 1, 2, 3, 4 or 5;

R_4 is selected from the group consisting of halogen, -R, -OR and =O

; R is independently selected from the group consisting of H and C₁₋₈ alkyl.

2. The compound according to claim 1, characterized in that, R₁ is selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the above C₁₋₆ alkyl is optionally substituted by one or more R₄.

3. The compound according to claim 2, characterized in that, R₁ is selected from the group consisting of C₁₋₆ alkyl, wherein the above C₁₋₆ alkyl is optionally substituted by one or more R₄.


4. The compound according to claim 1, characterized in that, R₂ is selected from the group consisting of hydrogen, cyano and -CONH₂.















5. The compound according to claim 1, characterized in that, B is selected from the group consisting of phenyl and pyridyl.


6. The compound according to claim 1, characterized in that, L₃ is selected from the group consisting of C₀₋₆ alkylene, wherein the above C₀₋₆ alkylene is optionally substituted by one or more R₄.


7. The compound according to claim 1, characterized in that, R_3 is selected from the group consisting of hydrogen, amino, C_{1-6} alkyl and 3-8 membered heterocyclohydrocarbonyl, wherein the above amino, C_{1-6} alkyl and 3-8 membered heterocyclohydrocarbonyl are optionally substituted by one or more R_4 ; or R_3 and L_3 together with the adjacent atom at the ring B form a saturated or unsaturated 5-8 membered ring, the 5-8 membered ring is optionally substituted by one or more R_4 .

8. A compound of the following formula:









or a pharmaceutically acceptable salt thereof.

9. Use of the compound according to any one of claims 1-8 or the pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating viral infection.

10. A pharmaceutical composition, comprising the compound according to any one of claims 1-8 or the pharmaceutically acceptable salt thereof in a therapeutically effective amount and one or more pharmaceutically acceptable carriers or excipients.